Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Cholangiocarcinoma (CCA) exhibits clinical heterogeneity, with distinct presentations between intrahepatic and extrahepatic forms.
• Next-generation sequencing (NGS) offers a powerful tool to elucidate genetic disparities between CCA subtypes.
• Identifying molecular subgroups within CCA is crucial for developing targeted therapeutic approaches.

Purpose of the Study:

• To investigate the genetic differences between intrahepatic and extrahepatic cholangiocarcinoma (CCA) using NGS.
• To correlate genetic aberrations (GAs) with clinical outcomes and prognostic implications in CCA patients.
• To identify potential therapeutic targets based on identified molecular alterations in CCA.

Main Methods:

• Successful NGS-based testing was performed on 75 CCA patients.
• Mutation profiling utilized either a targeted gene panel (46 genes) or whole-exome sequencing (236 genes).
• Clinical data was analyzed and correlated with patient outcomes, with referrals for targeted clinical trials based on actionable mutations.

Main Results:

• Significant genetic differences were observed between intrahepatic (n=55) and extrahepatic (n=20) CCA.
• Intrahepatic CCA showed higher frequencies of IDH1 and DNA repair gene alterations, while extrahepatic CCA had more ERBB2 GAs.
• Specific GAs (e.g., KRAS, TP53 in intrahepatic; BAP1, PBRM1 in extrahepatic) were associated with prognosis and bone metastases, with observed clinical benefit from targeted inhibitors.

Conclusions:

• Intrahepatic and extrahepatic cholangiocarcinoma (CCA) possess distinct genetic profiles.
• NGS technology is effective in identifying these genetic differences.
• The identified molecular subgroups have significant prognostic and therapeutic implications for CCA management.